Click here to close now.




















Welcome!

News Feed Item

Bone Cancer Global Clinical Trials Review, H1, 2014

LONDON, April 22, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Bone Cancer Global Clinical Trials Review, H1, 2014

http://www.reportbuyer.com/pharma_healthcare/drug_discovery/bone_cancer_global_clinical_trials_review_h1_2014.html

Bone Cancer Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, "Bone Cancer Global Clinical Trials Review, H1, 2014" provides data on the Bone Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bone Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bone Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Bone Cancer 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Bone Cancer to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Bone Cancer to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Bone Cancer 25
Subjects Recruited Over a Period of Time 31
Clinical Trials by Sponsor Type 32
Prominent Sponsors 33
Top Companies Participating in Bone Cancer Therapeutics Clinical Trials 34
Prominent Drugs 36
Latest Clinical Trials News on Bone Cancer 37
Jan 03, 2014: Eleison Announces Achievement of Enrollment Milestone in its Phase II Trial of ILC for Pediatric Bone Cancer 37
Oct 22, 2012: Eleison Enrolls First Patient In Phase II Trial Of Cisplatin For Pediatric Bone Cancer 37
Aug 07, 2012: Philips And Celsion Announce FDA Clearance To Commence Phase II Study Of ThermoDox And MR-Guided HIFU In Bone Cancer 37
Mar 02, 2012: Niiki Pharma To Begin Phase I Trial Of NKP-2235 38
Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model 38
Clinical Trial Profiles 40
Clinical Trial Overview of Top Companies 40
Novartis AG 40
Clinical Trial Overview of Novartis AG 40
F. Hoffmann-La Roche Ltd. 46
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 46
Amgen Inc. 48
Clinical Trial Overview of Amgen Inc. 48
Bayer AG 50
Clinical Trial Overview of Bayer AG 50
Takeda Pharmaceutical Company Limited 52
Clinical Trial Overview of Takeda Pharmaceutical Company Limited 52
Merck & Co., Inc. 53
Clinical Trial Overview of Merck & Co., Inc. 53
Pfizer Inc. 54
Clinical Trial Overview of Pfizer Inc. 54
AstraZeneca PLC 55
Clinical Trial Overview of AstraZeneca PLC 55
Eli Lilly and Company 56
Clinical Trial Overview of Eli Lilly and Company 56
Algeta ASA 57
Clinical Trial Overview of Algeta ASA 57
Clinical Trial Overview of Top Institutes / Government 58
National Cancer Institute 58
Clinical Trial Overview of National Cancer Institute 58
Children's Oncology Group 67
Clinical Trial Overview of Children's Oncology Group 67
The University of Texas M. D. Anderson Cancer Center 70
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 70
Memorial Sloan Kettering Cancer Center 72
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 72
Massachusetts General Hospital 74
Clinical Trial Overview of Massachusetts General Hospital 74
European Organization for Research and Treatment of Cancer 75
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 75
Southwest Oncology Group 76
Clinical Trial Overview of Southwest Oncology Group 76
University Health Network 77
Clinical Trial Overview of University Health Network 77
Stanford University 78
Clinical Trial Overview of Stanford University 78
Five Key Clinical Profiles 79
Appendix 180
Abbreviations 180
Definitions 180
Research Methodology 181
Secondary Research 181
About GlobalData 182
Contact Us 182
Disclaimer 182
Source 183

List of Tables

Bone Cancer Therapeutics, Global, Clinical Trials by Region, 2014* 7
Bone Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Bone Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Bone Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Bone Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Bone Cancer Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Bone Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Bone Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Bone Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Bone Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Bone Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Bone Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Bone Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Bone Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Bone Cancer Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Bone Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Bone Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Bone Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Bone Cancer Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Bone Cancer Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Bone Cancer Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Bone Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Bone Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 32
Bone Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Bone Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 35
Bone Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 40
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 46
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 48
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 50
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014* 52
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 53
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 54
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 55
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 56
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Algeta ASA, 2014* 57
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 58
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Oncology Group, 2014* 67
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 70
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 72
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 74
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014* 75
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Southwest Oncology Group, 2014* 76
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by University Health Network, 2014* 77
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 78

List of Figures

Bone Cancer Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Bone Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Bone Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Bone Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Bone Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Bone Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Bone Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Bone Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Bone Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Bone Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Bone Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Bone Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Bone Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Bone Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Bone Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Bone Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Bone Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Bone Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Bone Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 32
Bone Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Bone Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 34
Bone Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
GlobalData Methodology 181

Read the full report:
Bone Cancer Global Clinical Trials Review, H1, 2014

http://www.reportbuyer.com/pharma_healthcare/drug_discovery/bone_cancer_global_clinical_trials_review_h1_2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Skeuomorphism usually means retaining existing design cues in something new that doesn’t actually need them. However, the concept of skeuomorphism can be thought of as relating more broadly to applying existing patterns to new technologies that, in fact, cry out for new approaches. In his session at DevOps Summit, Gordon Haff, Senior Cloud Strategy Marketing and Evangelism Manager at Red Hat, discussed why containers should be paired with new architectural practices such as microservices rathe...
In their Live Hack” presentation at 17th Cloud Expo, Stephen Coty and Paul Fletcher, Chief Security Evangelists at Alert Logic, will provide the audience with a chance to see a live demonstration of the common tools cyber attackers use to attack cloud and traditional IT systems. This “Live Hack” uses open source attack tools that are free and available for download by anybody. Attendees will learn where to find and how to operate these tools for the purpose of testing their own IT infrastructu...
SYS-CON Events announced today that IceWarp will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. IceWarp, the leader of cloud and on-premise messaging, delivers secured email, chat, documents, conferencing and collaboration to today's mobile workforce, all in one unified interface
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
It’s been proven time and time again that in tech, diversity drives greater innovation, better team productivity and greater profits and market share. So what can we do in our DevOps teams to embrace diversity and help transform the culture of development and operations into a true “DevOps” team? In her session at DevOps Summit, Stefana Muller, Director, Product Management – Continuous Delivery at CA Technologies, answered that question citing examples, showing how to create opportunities for ...
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, will discuss how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a prac...
With the proliferation of connected devices underpinning new Internet of Things systems, Brandon Schulz, Director of Luxoft IoT – Retail, will be looking at the transformation of the retail customer experience in brick and mortar stores in his session at @ThingsExpo. Questions he will address include: Will beacons drop to the wayside like QR codes, or be a proximity-based profit driver? How will the customer experience change in stores of all types when everything can be instrumented and a...
Red Hat is investing in Tesora, the number one contributor to OpenStack Trove Database as a Service (DBaaS) also ranked among the top 20 companies contributing to OpenStack overall. Tesora, the company bringing OpenStack Trove Database as a Service (DBaaS) to the enterprise, has announced that Red Hat and others have invested in the company as a part of Tesora's latest funding round. The funding agreement expands on the ongoing collaboration between Tesora and Red Hat, which dates back to Febr...
The Internet of Things (IoT) is about the digitization of physical assets including sensors, devices, machines, gateways, and the network. It creates possibilities for significant value creation and new revenue generating business models via data democratization and ubiquitous analytics across IoT networks. The explosion of data in all forms in IoT requires a more robust and broader lens in order to enable smarter timely actions and better outcomes. Business operations become the key driver of I...
SYS-CON Events announced today that DataClear Inc. will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. The DataClear ‘BlackBox’ is the only solution that moves your PC, browsing and data out of the United States and away from prying (and spying) eyes. Its solution automatically builds you a clean, on-demand, virus free, new virtual cloud based PC outside of the United States, and wipes it clean...
Culture is the most important ingredient of DevOps. The challenge for most organizations is defining and communicating a vision of beneficial DevOps culture for their organizations, and then facilitating the changes needed to achieve that. Often this comes down to an ability to provide true leadership. As a CIO, are your direct reports IT managers or are they IT leaders? The hard truth is that many IT managers have risen through the ranks based on their technical skills, not their leadership ab...
A producer of the first smartphones and tablets, presenter Lee M. Williams will talk about how he is now applying his experience in mobile technology to the design and development of the next generation of Environmental and Sustainability Services at ETwater. In his session at @ThingsExpo, Lee Williams, COO of ETwater, will talk about how he is now applying his experience in mobile technology to the design and development of the next generation of Environmental and Sustainability Services at ET...
Cloud and datacenter migration innovator AppZero has joined the Microsoft Enterprise Cloud Alliance Program. AppZero is a fast, flexible way to move Windows Server applications from any source machine – physical or virtual – to any destination server, in any cloud or datacenter, using its patented container technology. AppZero’s container is also called a Virtual Application Appliance (VAA). To facilitate Microsoft Azure onboarding, AppZero has two purpose-built offerings: AppZero SP for Azure,...
WSM International, the pioneer and leader in server migration services, has announced an agreement with WHOA.com, a leader in providing secure public, private and hybrid cloud computing services. Under terms of the agreement, WSM will provide migration services to WHOA.com customers to relocate some or all of their applications, digital assets, and other computing workloads to WHOA.com enterprise-class, secure cloud infrastructure. The migration services include detailed evaluation and planning...
This Enterprise Strategy Group lab validation report of the NEC Express5800/R320 server with Intel® Xeon® processor presents the benefits of 99.999% uptime NEC fault-tolerant servers that lower overall virtualized server total cost of ownership. This report also includes survey data on the significant costs associated with system outages impacting enterprise and web applications. Click Here to Download Report Now!